Azstarys™ (serdexmethylphenidate/dexmethylphenidate) – New drug approval
March 2, 2021 - KemPharm announced the FDA approval of Azstarys (serdexmethylphenidate/dexmethylphenidate), for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older.
Download PDF
